Jounce Therapeutics, Inc. (JNCE) PT Set at $28.00 by J P Morgan Chase & Co
Jounce Therapeutics, Inc. (NASDAQ:JNCE) has been given a $28.00 price objective by stock analysts at J P Morgan Chase & Co in a research report issued on Monday. The brokerage presently has a “buy” rating on the stock. J P Morgan Chase & Co’s price target suggests a potential upside of 89.06% from the company’s previous close.
Several other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Jounce Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Robert W. Baird restated a “buy” rating and issued a $30.00 price objective on shares of Jounce Therapeutics in a report on Friday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $23.67.
Shares of Jounce Therapeutics (NASDAQ:JNCE) opened at $14.81 on Monday. Jounce Therapeutics has a fifty-two week low of $11.05 and a fifty-two week high of $29.29.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. acquired a new position in Jounce Therapeutics in the 3rd quarter valued at about $124,000. American International Group Inc. grew its position in Jounce Therapeutics by 132.2% in the 3rd quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after acquiring an additional 5,442 shares in the last quarter. Teachers Advisors LLC grew its position in Jounce Therapeutics by 26.4% in the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after acquiring an additional 2,347 shares in the last quarter. Ark Investment Management LLC grew its position in Jounce Therapeutics by 558.9% in the 2nd quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock valued at $167,000 after acquiring an additional 10,121 shares in the last quarter. Finally, Nationwide Fund Advisors grew its position in Jounce Therapeutics by 203.3% in the 2nd quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock valued at $168,000 after acquiring an additional 8,007 shares in the last quarter. 44.47% of the stock is owned by institutional investors.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.